Population pharmacokinetics and therapeutic response of CGP 56697 (artemether + benflumetol) in malaria patients

British Journal of Clinical Pharmacology

Volumn 46, Issue 6, 1998, Pages 553-561

  Ezzet, Farkad ^a   Karbwang, Juntra ^b  

^a NOVARTIS PHARMA AG   (Switzerland)

^b MAHIDOL UNIVERSITY   (Thailand)

Author keywords

Artemether; Benflumetol; Bioavailability; Malaria; Population pharmacokinetics; Therapeutic response

Indexed keywords

ANTIMALARIAL AGENT; ARTEMETHER;

ADOLESCENT; ADULT; AREA UNDER THE CURVE; ARTICLE; CHINA; CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MIXTURE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALARIA; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THAILAND; TREATMENT FAILURE;

ADOLESCENT; ADULT; ANTIMALARIALS; ARTEMISININS; DOUBLE-BLIND METHOD; DRUG COMBINATIONS; ETHANOLAMINES; FEMALE; FLUORENES; HUMANS; MALARIA; MALE; MIDDLE AGED; SESQUITERPENES; TREATMENT OUTCOME;

EID: 0031753648     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.1998.00830.x     Document Type: Article

References (34)

1. Looareesuwan S, Harinasuta T, Chongsuphajaisiddhi T. Drug resistant malaria with special reference to Thailand. Southeast AsiaJ Trop Med Public Health 1992; 23: 621-634.
2. Looareesuwan S, Vivaran C, Vanijanonta P, Wilairatana P, Pitisuttithum P, Andrial M. Comparative clinical trial of artesunate followed by mefloquine in the treatment of uncomplicated falciparum malaria: two- and three-day regimens. Am J Trop Med Hyg 1996; 54: 210-213.
3. Mull R, Jiao Xeu-Qing. The comparative efficacy and tolerability of Coartem (CGP 56697) and benflumetol in the treatment of patients with plasmodium falciparum infection in China. 1998 (in preparation).
4. de Vries PJ, Dien TK. Clinical pharmacology and therapeutic potential of artemisinin and its derivatives in the treatment of malaria. Drugs 1996; 52: 818-836.
5. Dunnag D, Viravan C, Looareesuwan S, Karbwang J, Harinasuta T. Clinical trial of artesunate and artemether on multidrug resistant P. falcipanim malaria in Thailand. Southeast Asian J Trop Med Public Health 1991; 22: 380-385.
6. KarbwangJ, Na Bangchang K, Thanavibul A, Dunnag D, Chongsuphajaisiddhi T, Harinasuta T. Comparison of oral artemcthcr and quinine in uncomplicated falciparum malaria. Lancet 1992; 340: 1245-1248.
7. Sheiner LB, Roscnberg B, Marathe VV. Estimation of population characteristics of pharmacokinetic parameters from routine clinical data._/ Pharmacokinetic Biophami 1977; 5: 445-479.
8. Benflumetol registration dossier. Institute of Microbiology and Epidemiology, Academy of Military Medical Sciences (AMMS), Beijing, PRC 1993.
9. Lew AM, Marshall VM, Kcmp DJ. Affinity selection of polymcrase chain reaction products by DNA-binding proteins. Meth-Enzymol 1993; 218: 526-534.
10. Nelson K, Seiander RK. Analysis of genetic variation by polymerase chain reaction-based nucleotide sequencing. MethEnzymol 1994; 235: 174-183.
11. Wooden J, Kycs S, Sibley CH. PCR and strain identification in Plasmodiwn falciparwn. Parasitai Today 1993; 9: 303-305.
12. World Health Organisation. Chemotherapy of Malaria and Resistance to Antimalarials. Geneva WHO Technical Report 1973, Series no.; 529: 30-36.
13. Zeng MY, Lu ZL, Yang SC, et al. Determination of benflumetol in human plasma by rcvcrsed-phase highperformance liquid chromatography with ultraviolet detection. J Chromatogr 1996; 681: 299-306.
14. Sandrenan N, Sioufi A, Godbillon J, Netter C, Donker M, van Valkenburg C. Determination of artemether and its metabolite, dihydroartemisinin, in plasma by highperformance liquid chromatography and electrochemical detection in the reductive mode. J Chromatogr 1997; 691: 145-153.
15. Mathsoft Version 3. 4 for Unix Supplement, Data analysis Products Division, Mathsoft, Seattle 1996.
16. Lindstrom MJ, Bates DM. Nonlinear mixed effects models for repeated measures data. Biometrics 1990; 46: 673-687.
17. Davidian M, Giltinan AR. Nonlinear models for repeated measurements data. Chapman and Hall, London 1995.
18. Gibaldi M, Perrier D. Phannacokinetics, 2nd edn. Marcel Dekker Inc., New York 1982.
19. Ezzet F, Eisele J. Inter-occasion variation in the bioavailability of benflumetol (an anti malarial drug). Presented at Population Approach Group in Europe, June 1996 (Abstract).
20. Mordi MN, Mansor SM, Navaratnam V, Wemsdorfer WH. Single dose pharmacokinetics of oral artemether in healthy Malasian volunteers. BrJ Clin Phannacol 1997; 43: 363-365.
21. SAS Institute Inc SAS, /STAT. User's Guide, Version, 6, 4th edn, Vol. 2, Cary, NC. SAS Institute Inc. 1989.
22. White NJ, Krishna S. Treatment of malaria: some consideration and limitations of the current methods of assessment. Trans R Soc Trop Mcd Hyg 1989; 83: 767-777.
23. Hussein Z, Eaves CJ, Hutchinson DB, Canfield CJ. Population pharmacokinetics of proguanil in patients with acute P. falciparum malaria after combined therapy with atovaquone. BrJ Clin Pliarmacol 1996; 42: 589-597.
24. Hussein Z, Eaves J, Hutchinson DD, Canfield CJ. Population pharmacokinetics of atovaquone in patients with acute malaria caused by plasmodium falciparum. Clin Pliarmacol Tlicr 1997; 61: 518-530.
25. Sidhu JS, Ashton M, Huong NV, et al. Artemisinin population pharmacokinetics in children and adults with uncomplicated falciparum malaria. BrJ Clin Plianiiacol 1998; 45: 347-354.
26. Teja-Isavadharm P, Nosten F, Kyle DE, et al. Comparative bioavailability of oral, rectal, and intramuscular artemether in healthy subjects: use of simultaneous measurement by high performance liquid chromatography and bioassay. BrJ Clin Pliarmacol 1996; 42: 599-604.
27. Welling PG. Effects of food on drug absorption. Pliarmac Tlier 1989; 43: 425-441.
28. Bindshcdler M, Degen P, Lu ZL, et al. Comparative bioavailability of benflumctol after administration of single oral doses of co-artemether under fed and fasted conditions to healthy subjects. Abstract for X/Hr/i International Congress for Tropical Medicine and Malaria, Nagasaki, Japan, Nov. 17-22 1996.
29. Wilkinson GR. Cytochrome P4503A (CYP3A) metabolism: Prediction of m vivo activity in humans. J Phannacokin Biophann 1996; 24: 474-490.
30. Edwards G. Measurement of artemisinin and its derivatives in biological fluids. Trans R Soc Trop Mcd Hyg 1994; 88(Suppl 1): 37-39.
31. Hassan-Alin M, Ashton M, Kihamia CM, Mtey GJB, Bjorkman A. Clinical efficacy and pharmacokinetics of artemisinin monotherapy and in combination with mefloquine in patients with falciparum malaria. BrJ Clin Pliarmacol 1996; 41: 587-592.
32. White NJ. Clinical pharmacokinetics and pharmacodynamics of artemisinin and derivatives. Trans R Soc Trop Med Hyg 1994; 88(Suppl 1): 41-43.
33. Ashton M, Hai TN, Sy ND et al. Artemisinin pharmacokinetics is time-dependent during repeated oral administration is healthy male adults. Drug Metab Dispos 1998; 26: 25-27.
34. White NJ. Assessment of the pharmacodynamic properties of antimalarial drugs in vivo. J Antimicrob Clienwther 1997; 41: 1413-1422.